Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Liposomal amphotericin B may be effective in controlling fever and granulocytopenia. It is not yet known which regimen of liposomal amphotericin B is more effective in treating cancer patients who have these conditions.

PURPOSE: Randomized phase III trial to compare the effectiveness of two regimens of liposomal amphotericin B in treating granulocytopenia and fever in cancer patients.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
• Treatments: Amphotericin B; Liposomal amphotericin B

Criteria

DISEASE CHARACTERISTICS:

• Hematologic malignancy or solid tumor

• Must be undergoing remission induction and/or consolidation therapy for hematologic malignancy only OR

• Must be undergoing allogeneic or autologous bone marrow transplantation

• Granulocyte count less than 500/mm^3 and profound granulocytopenia expected to last for greater than 5 days

• Fever (greater than 38.5 degrees C) refractory for greater than 72 hours and less than 84 hours to broad spectrum antimicrobials, after exclusion of current bacterial, fungal, viral, parasitic, and mycobacterial infections

• Peripheral blood cultures and central venous catheter cultures negative for infections

• No microbiological documentation of a bacterial infection (e.g., abscess at catheter site)

• No invasive fungal infection

• No probable noninfectious cause of fever

PATIENT CHARACTERISTICS:

Age:

• Not specified

Performance status:

• Karnofsky 40-100% OR

• WHO 0-2

Life expectancy:

• Not specified

Hematopoietic:

• See Disease Characteristics

Hepatic:

• Not specified

Renal:

• Not specified

Other:

• No prior anaphylactic reaction to amphotericin B

• No psychological, familial, sociological, or geographical conditions that would prevent compliance

• Not pregnant or nursing

• Normal chest X-ray or normal high resolution CT scan of the lungs

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• See Disease Characteristics

Chemotherapy:

• See Disease Characteristics

Endocrine therapy:

• Not specified

Radiotherapy:

• Not specified

Surgery:

• Not specified

Other:

• No concurrent active systemic antifungal agents or antifungal prophylaxis (e.g., azoles or polyenes)

• No prior IV amphotericin B during same neutropenic episode

• No change in antibacterial regimen within 48 hours prior to study